Service advice and planning
39 results
Applied filters
Risk assessing Investigational Medicinal Products (IMPs)
29 April 2026Sponsor pharmacy responsibilities when assessing the risk associated with CTIMPs.
Additional considerations for single or multi-centre trials
29 April 2026Ensure the correct process is followed depending on whether it is a single or multi-centre trial sponsored by an NHS organisation.
Constructing a pharmacy manual for clinical trials
29 April 2026Sponsor pharmacy should construct a pharmacy manual when required by the sponsor to facilitate IMP and NIMP management by the different delivery location sites.
Supply and administration of medicines by staff group (P to Z)
1 April 2026Different staff groups have different permissions with respect to medicines supply and administration and it is important to ensure legislation is followed.
Legal mechanisms to supply and administer medicines to individuals
1 April 2026The main legal mechanisms used to supply and/or administer medicines are explained and considerations suggested for the most appropriate option(s)
Supply and administration of medicines by staff group (H to O)
1 April 2026Different staff groups have different permissions with respect to medicines supply and administration and it is important to ensure legislation is followed.
Supply and administration of medicines by staff group (A to G)
1 April 2026Different staff groups have different permissions with respect to medicines supply and administration and it is important to ensure legislation is followed.
Managing controlled drugs for dental teams
16 March 2026This article provides an overview of controlled drug (CD) management for dental teams
In-vivo GMO gene therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing in-vivo genetically modified organism (GMO) gene therapy.
Ex-vivo GMO gene therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing ex-vivo genetically modified organism (GMO) gene therapy.